CONTENTS VOL. 17, 1999

Volume 17, No. 1

Preclinical Studies

Activity and DNA binding of new organoamidoplatinum (II) complexes – T. Talarico, D.R. Phillips, G.B. Deacon, S. Rainone, L.K. Webster 1–15

Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin – T.H. Corbett, C. Panchapor, L. Polin, N. Lowichik, S. Pugh, K. White, J. Kushner, J. Meyer, J. Czarnecki, S. Chinnukroh, M. Edelstein, P. LoRusso, L. Heilbrun, J.P. Horwitz, C. Grieshaber, R. Perni, M. Wentland, S. Coughlin, S. Elenbaas, R. Philion, J. Rake 17–27

Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice – R. van Gijn, O. van Tellingen, E. Haverkate, J.J. Kettenes-van den Bosch, A. Bult, J.H. Beijnen 29–41

Review Article

Current status of pyrazoloacridine as an anticancer agent – A.A. Adjei 43–48

Phase I Studies

A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of ^{14}C-labelled drug – I.R. Judson, P.J. Beale, J.M. Trigo, W. Aherne, T. Crompton, D. Jones, E. Bush, B. Reigner 49–56

Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study – E. Poplin, J. Roberts, M. Tombs, S. Grant, E. Rubin 57–62

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) – K.D. Tutsch, R.Z. Arzoomanian, D. Alberti, M.B. Tombes, C. Feierabend, H.I. Robins, D.R. Spriggs, G. Wilding 63–72

A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer – D. Rischin, L.K. Webster, M.J. Millward, G.C. Toner, S. Nawaratne, V. Ganju, P. Francis, J.F. Bishop 73–80

Phase I study of liposomal daunorubicin in patients with acute leukemia – J. Cortes, S. O'Brien, E. Estey, F. Giles, M. Keating, H. Kantarjian 81–87

Phase II Studies

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study – N. Vey, H. Kantarjian, M. Beran, S. O'Brien, J. Cortes, C. Koller, E. Estey 89–95

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma – S. Mani, D. Sciortino, B. Samuels, R. Arrietta, R.L. Schilsky, E.E. Vokes, S. Benner 97–101

Volume 17, No. 2

Preclinical Studies

Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist – trihydrochloride of {1,2,5-trimethyl-4-phenyl-4-β-[N-(β-ethylamino)-N- 4′-methoxybenzyl]-ethylamino} piperidine (AR-2) – A.R. Alexanian, N.S. Arutyunian 105–110

Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule – M. Eatock, N. Church, R. Harris, W. Angerson, C. McArdle, R. French, C. Twelves 111–120

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy – C.J. Dimitroff, W. Klohs, A. Sharma, P. Pera, D. Driscoll, J. Veith, R. Steinkampf, M. Schroeder, S. Klutchko, A. Sumlin, B. Henderson, T.J. Dougherty, R.J. Bernacki 121–135

Review Articles

RAS inhibitors in hematologic cancers: biologic considerations and clinical applications – D.M. Beaupre, R. Kurzrock 137–143

Ethical issues in the development of new agents – C.K. Daugherty 145–153

Phase I Study

A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials – P.F. Thall, E.H. Estey, H.-G. Sung 155–167

Phase II Studies

Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial – D.F. Moore, Jr., T.D. Brown, M. LeBlanc, S. Dahlberg, T.P. Miller, S. McClure, R.I. Fisher 169–172

A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer – R.S. Witte, S. Lipsitz, T.L. Goodman, R.F. Asbury, G. Wilding, C.M. Strnad, T.J. Smith, D.G. Haller 173–177

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or Glioblastoma multiforme (NSC 325319) – A. Mittelman, H.G. Chun, C. Puccio, N. Coombe, T. Lansen, T. Ahmed 179–182

Phase II trial of suramin in patients with metastatic renal cell carcinoma – R. Dreicer, D.C. Smith, R.D. Williams, W.A. See 183–186

Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination – J.E. Romaguera, M.A. Rodriguez, F.B. Hagemeister, P. McLaughlin, J. Rodriguez, A. Preti, A. Younes, A.H. Sarris, F. Cabanillas 187–192

Volume 17, No. 3

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor – Z. Zhu, L. Witte 195–212

Tyrosine kinase inhibitors in preclinical development – M.L. Levitt, P.P. Koty 213–226

Protein kinase C targeting in antineoplastic treatment strategies – W.D. Jarvis, S. Grant 227–240

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway – D.W. End 241–258

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results – S.-M. Huang, P.M. Harari 259–269

Antiandrogens in prostate cancer – P. Reid, P. Kantoff, W. Oh 271–284

Antiestrogens – tamoxifen, SERMs and beyond – K. Dhingra 285–311

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials – A.M. Senderowicz 313–320

Announcement 321

Volume 17, No. 4

Preclinical studies

A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography – UV detection: validation and suitability in phase I clinical trial pharmacokinetics – C.J. Ardiet, B. Tranchand, S. Zanetta, A. Guillot, E. Bernard, M. Peguy, P. Rebattu, J.-P. Droz 325–333

Activation-induced apoptosis of peripheral lymphocytes treated with 7-hydroxystaurosporine, UCN-01 – H. Fukumoto, T. Tamura, Y. Kamiya, J. Usuda, T. Suzuki, F. Kanzawa, H.-J. Kuh, Y. Ohe, N. Saijo, K. Nishio 335–341

Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic – R.M. Hoffman 343–360

Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity – L. Neckers, T.W. Schulte, E. Mimnaugh 361–373

Novel anticancer therapeutics

Oncolytic viruses – J. Nemunaitis 375–386

Matrix metalloproteinase inhibitors: applications in oncology – D. Yip, A. Ahmad, C.S. Karapetis, C.A. Hawkins, P.G. Harper 387–399

Oral topoisomerase 1 inhibitors: in adult patients – H.A.J. Gelderblom, M.J.A. de Jonge, A. Sparreboom, J. Verweij 401–415

Toward checkmate: Biology and breast cancer therapy for the new millennium – K.D. Miller, G.W. Sledge Jr. 417–427

Contents Volume 17, 1999 429–431

Author Index 433–434

Instructions for authors 435–436